Insmed Incorporated (INSM)
NASDAQ · Healthcare · Biotechnology
Profile
Insmed Incorporated
- Exchange
- NASDAQ
- Ticker
- INSM
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Key facts
Insmed Incorporated: key facts
- Insmed Incorporated (NASDAQ: INSM) is a Biotechnology company in the Healthcare sector.
- In fiscal 2025, Insmed Incorporated reported revenue of $606.4M and net income of -$1.3B.
- Revenue grew 33.9% a year over the last 4 fiscal years.
- Free cash flow was positive in 0 of the last 5 fiscal years.
- Net income was positive in 0 of the last 5 fiscal years.
- Over the last twelve months, revenue was $1.5B and net income was -$605.6M.
MonkScore
Insmed Incorporated's MonkScore
MonkScore
MonkScore range: 80–90
as of October 2026
Sector rank: 105 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth90–100
- Profitability70–80
- Quality40–50
- Market Conviction90–100
- Safety30–40
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Insmed Incorporated's annual figures and the last twelve months, in USD. Last report: 30 September 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $1.5B | $606.4M | $363.7M | $305.2M | $245.4M | $188.5M |
| Gross profit | $1.3B | $481.5M | $278.0M | $239.6M | $190.2M | $144.3M |
| Operating income | -$540.9M | -$1.2B | -$878.3M | -$709.6M | -$457.3M | -$375.1M |
| Net income | -$605.6M | -$1.3B | -$913.8M | -$749.6M | -$481.5M | -$434.7M |
| Operating cash flow | -$595.6M | -$935.0M | -$683.9M | -$536.2M | -$400.4M | -$363.3M |
| Capital expenditure | -$62.0M | -$32.6M | -$21.9M | -$13.3M | -$9.9M | -$7.3M |
| Free cash flow | -$657.6M | -$967.6M | -$705.8M | -$549.5M | -$410.3M | -$370.6M |
| Total debt | $741.2M | $768.2M | $1.3B | $1.2B | $1.2B | $612.3M |
| Cash | $396.6M | $510.4M | $555.0M | $482.4M | $1.1B | $716.8M |
Revenue growth a year
- 1-year
- 66.7%
- 3-year
- 35.2%
- 4-year
- 33.9%
Compound growth between fiscal years.
Peers
Similar companies
- Madrigal Pharmaceuticals, Inc.NASDAQ:MDGLMonkScore range: 80–90
- MeiraGTx Holdings plcNASDAQ:MGTXMonkScore range: 80–90
- Exelixis, Inc.NASDAQ:EXELMonkScore range: 90–100
- Axsome Therapeutics, Inc.NASDAQ:AXSMMonkScore range: 90–100
- Adaptive Biotechnologies CorporationNASDAQ:ADPTMonkScore range: 90–100
- Neurocrine Biosciences, Inc.NASDAQ:NBIXMonkScore range: 90–100
- 10x Genomics, Inc.NASDAQ:TXGMonkScore range: 90–100
- Protagonist Therapeutics, Inc.NASDAQ:PTGXMonkScore range: 90–100
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.